Evidence map›Paper›PMID 33875484›Full record

Trial reportDiabetes care2021

A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100.

Ildiko Lingvay, John B Buse, Edward Franek, Melissa V Hansen, Mette M Koefoed, Chantal Mathieu, Jeremy Pettus, Karolina Stachlewska, Julio Rosenstock

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 8 pooled it
11.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 8 syntheses or guidelines pooled it, 92 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Once-Weekly Insulin IcodecArchives of endocrinology and metabolism · 2023
    Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 4 countries.

Ildiko LingvayEndocrinology Division, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX ildiko.lingvay@utsouthwestern.edu.ORCID 0000-0001-7006-7401
John B BuseSchool of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Edward FranekMossakowski Medical Research Centre, Warsaw, Poland.
Melissa V HansenNovo Nordisk A/S, Søborg, Denmark.
Mette M KoefoedNovo Nordisk A/S, Søborg, Denmark.
Chantal MathieuClinical and Experimental Endocrinology, University of Leuven, Leuven, Belgium.ORCID 0000-0002-6099-2406
Jeremy PettusSchool of Medicine, University of California, San Diego, San Diego, CA.
Karolina StachlewskaNovo Nordisk A/S, Søborg, Denmark.
Julio RosenstockDallas Diabetes Research Center at Medical City, Dallas, TX.ORCID 0000-0001-8324-3275
Novo Nordisk (Denmark) · DKDallas Diabetes Research Center · USKU Leuven · BEMossakowski Medical Research Institute, Polish Academy of Sciences · PLThe University of Texas Southwestern Medical Center · USUniversity of California San Diego · USUniversity of North Carolina at Chapel Hill · US

Funding

Re-Entry Supplement: Investigation of Oral Microbial Enzymes for the Detection and Treatment of Periodontal DiseaseUL1TR002489 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, SHAHEEN, NICHOLAS J · 2018 to 2022
$48.6M
Pilot & Feasibility ProgramP30DK124723 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI P Darrell Neufer · 2020 to 2026
$11.0M
NCATS NIH HHS UL1 TR002489NIDDK NIH HHS P30 DK124723
6 · The paper itself

Abstract

objectiveInsulin icodec is a novel once-weekly basal insulin analog. This trial investigated the efficacy and safety of icodec using different once-weekly titration algorithms. RESEARCH DESIGN AND

methodsThis was a phase 2, randomized, open-label, 16-week, treat-to-target study. Insulin-naive adults (

resultsTIR improved from baseline (means: A, 57.0%; B, 55.2%; C, 51.0%; IGlar U100, 55.3%) to weeks 15 and 16 (estimated mean: A, 76.6%; B, 83.0%; C, 80.9%; IGlar U100, 75.9%). TIR was greater for titration B than for IGlar U100 (estimated treatment difference 7.08%-points; 95% CI 2.12 to 12.04;

conclusionsOnce-weekly icodec was efficacious and well tolerated across all three titration algorithms investigated. The results for icodec titration A (80-130 mg/dL; ±21 units/week) displayed the best balance between glycemic control and risk of hypoglycemia.

Indexed as

Diabetes Mellitus, Type 2AdultBlood GlucoseBlood Glucose Self-MonitoringGlycated HemoglobinHumansHypoglycemic AgentsInsulin GlargineInsulin, Long-ActingBlood GlucoseGlycated HemoglobinHypoglycemic AgentsInsulin Glargineinsulin icodecInsulin, Long-Acting

Identifiers

PMID33875484
PMCPMC8323172
OpenAlexW3155901707

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.